Pfizer sees 'durable demand' for COVID-19 vaccine as it boosts sales forecast

globalnews.ca
3 min read
standard
Pfizer forecast US$26 billion in COVID-19 vaccine sales this year, a more than 70 per cent jump from its last projection,
Send this page to someone via email

Pfizer Inc on Tuesday raised its forecast for 2021 COVID-19 vaccine sales by more than 70 per cent to US$26 billion and said demand from governments around the world trying to halt the pandemic could contribute to its growth for years to come.

The company said it expects by the end of this month to file for full approval of the vaccine for people over the age of 16 in the United States, where it is currently only authorized for emergency use. It also expects to hear soon from U.S. regulators on the expansion of the vaccine's emergency use authorization (EUA) for children ages 12-15.

Revenue from the vaccine – developed with German partner BioNTech SE – is expected to account for more than one third of Pfizer's full-year sales this year.

The forecast is based on already signed contracts for 1.6 billion vaccine doses to be delivered this year. The company said it expects to sign more deals for this year and is in supply talks with several countries for 2022 and beyond.

Story continues below advertisement

"Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome," Chief Executive Albert Bourla said.

The two-shot vaccine was Pfizer's…
Manas Mishra and Michael Erman
Read full article